Fairmount Funds Management LLC - Aug 17, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Director, Other*, 10%+ Owner
Signature
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Funds Management LLC
Stock symbol
VRDN
Transactions as of
Aug 17, 2022
Transactions value $
$9,999,979
Form type
4
Date filed
8/19/2022, 04:32 PM
Previous filing
Jun 21, 2022
Next filing
Jun 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Purchase $10M +426K +45.35% $23.50 1.36M Aug 17, 2022 Fairmount Healthcare Fund II LP F2
holding VRDN Common Stock 5.86K Aug 17, 2022 Fairmount Healthcare Fund LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F2 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Remarks:

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.